Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development.

IF 13.1 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Abdoulaye Yalcouyé, Kevin Esoh, Ambroise Wonkam
{"title":"Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development.","authors":"Abdoulaye Yalcouyé, Kevin Esoh, Ambroise Wonkam","doi":"10.1146/annurev-pharmtox-071724-014737","DOIUrl":null,"url":null,"abstract":"<p><p>African populations remain largely underrepresented in genomic studies despite their high genetic diversity. The significant variability in drug efficacy and toxicity across different ancestry populations should trigger more diversified and inclusive pharmacogenomic (PGx) studies. Non-European populations, especially Africans, remain largely underrepresented in GWASs and other genomic studies despite their high genetic diversity, which holds information critical for better understanding drug-related toxicity and enhancing the development of new drugs. Therefore, studies using population genetic clustering, polygenic risk scores, high-throughput organoid models, and multiomics analysis are urgently needed in African populations to enhance pharmacogenomics and drug development globally. For instance, studies of loss-of-function mutations in <i>PCSK9</i>, commonly found in populations of African descent, have led to the development of PCSK9 inhibitors, which are used globally to reduce hypercholesterolemia and cardiovascular disease risk. More studies on diverse African populations could elevate PGx, drug development, and therapeutics as illustrated by the PCSK9 example.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":" ","pages":""},"PeriodicalIF":13.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-071724-014737","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

African populations remain largely underrepresented in genomic studies despite their high genetic diversity. The significant variability in drug efficacy and toxicity across different ancestry populations should trigger more diversified and inclusive pharmacogenomic (PGx) studies. Non-European populations, especially Africans, remain largely underrepresented in GWASs and other genomic studies despite their high genetic diversity, which holds information critical for better understanding drug-related toxicity and enhancing the development of new drugs. Therefore, studies using population genetic clustering, polygenic risk scores, high-throughput organoid models, and multiomics analysis are urgently needed in African populations to enhance pharmacogenomics and drug development globally. For instance, studies of loss-of-function mutations in PCSK9, commonly found in populations of African descent, have led to the development of PCSK9 inhibitors, which are used globally to reduce hypercholesterolemia and cardiovascular disease risk. More studies on diverse African populations could elevate PGx, drug development, and therapeutics as illustrated by the PCSK9 example.

为临床护理和药物开发加强非洲人群的大规模药物遗传学研究。
尽管非洲人口具有高度的遗传多样性,但其在基因组研究中的代表性仍然很大程度上不足。不同祖先人群中药物疗效和毒性的显著差异应该引发更多样化和包容性的药物基因组学(PGx)研究。非欧洲人口,特别是非洲人,在全球基因组分析和其他基因组研究中的代表性仍然不足,尽管他们的遗传多样性很高,这对更好地了解药物相关毒性和加强新药开发至关重要。因此,迫切需要在非洲人群中使用群体遗传聚类、多基因风险评分、高通量类器官模型和多组学分析进行研究,以加强全球药物基因组学和药物开发。例如,对在非洲裔人群中常见的PCSK9功能丧失突变的研究导致了PCSK9抑制剂的开发,这些抑制剂在全球范围内用于降低高胆固醇血症和心血管疾病的风险。如PCSK9的例子所示,对不同非洲人口进行更多的研究可以提高PGx、药物开发和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
27.80
自引率
0.00%
发文量
53
期刊介绍: Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信